Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / Liver Rapid Reference Set Application: Kevin Qu-Quest (2011)

Liver Rapid Reference Set Application: Kevin Qu-Quest (2011)

329
Qu, KevinQuest Diagnostics
Feng, ZidingFred Hutchinson Cancer Research Center
alpha-fetoprotein (AFP), AFP-L3%, and des-y-carboxy prothrombin (DCP).
Proteomics
G.I. and Other Associated Cancers Research Group

We propose to evaluate the performance of a novel serum biomarker panel for early detection of hepatocellular carcinoma (HCC). This panel is based on markers from the ubiquitin-proteasome system (UPS) in combination with the existing known HCC biomarkers, namely, alpha-fetoprotein (AFP), AFP-L3%, and des-y-carboxy prothrombin (DCP). To this end, we applied multivariate logistic regression analysis to optimize this biomarker algorithm tool.

We propose to evaluate the performance of a novel serum biomarker panel for early detection of hepatocellular carcinoma (HCC).
In the proposed study, we will not need a training set in addition to a blinded reference set. The HCC UPS model was selected from a working set that included patients with HCC (n=135), and CLD with cirrhosis (F3-4, n=148), with samples randomly assigned into 100 training sets and testing sets. The model was created using these training sets and evaluated in the testing sets by averaged error rates and area under the ROC (AUROC) curve analysis. The blinded reference set is designed to confirm the utility of the HCC UPS model. Our statisticians will perform all statistic analysis; Dr. Michael Walker, a professor at Stanford University, will monitor the statistical analysis. We will not need help from the EDRN if we do a larger Phase II validation study.

No datasets are currently associated with this protocol.


Announcement 03/14/2018
Thank you to everyone to made the 10th EDRN Scientific Workshop a success. The next event is the 33rd EDRN Steering Committee Meeting from September 5-6, 2018 in Boston, MA. Details will be available soon.


Three new FOAs on the Human Tumor Atlas and associated with the Cancer Moonshot Initiative have been released. Please click here for more information.

Announcement 10/23/2017

Three new FOAs on the Human Tumor Atlas and associated with the Cancer Moonshot Initiative have been released. Please click here for more information.

EDRN Founder Honored

Dr. Sudhir Srivastava was honored with the Distinguished Service Award from the American Pancreatic Association at the group's annual meeting this year, for his outstanding commitment to pancreatology.